Our Science

Ionizable Lipid Library:

Our platform is built on one of the largest proprietary ionizable lipid libraries in the field — rationally designed from over 100,000 structures, with more than 6,000 synthesized and screened through a rigorous funnel from cell-based assays through animal models to non-human primate studies. Three ionizable lipids are now in cGMP manufacturing. Our LNP formulations have demonstrated delivery beyond the liver — to immune cells, muscle, adipose, bone marrow, and other tissue types — a broad foundation that our targeted LNP platform further enhances with cell-type specificity.

Targeted LNP Platform:

Our targeted LNP platform combines antibody engineering with optimized conjugation chemistry to actively direct mRNA payloads to specific cell populations. The system was optimized through extensive DoE across LNP formulation, mRNA engineering, antibody selection, and conjugation process.

The therapeutic potential of mRNA depends on more than delivery alone. Innorna’s mRNA engineering capabilities optimize multiple layers of the molecule to maximize expression, duration, and tolerability while minimizing off-target immune activation. Our capabilities span a broad mRNA design space: proprietary UTR libraries for enhanced translational efficiency, codon optimization algorithms, poly(A) tail engineering, and capping chemistry for high translational fidelity. Each mRNA payload is purpose-built for its therapeutic context — whether encoding an enzyme for chronic protein replacement, an antigen for immune activation, or a binder for targeted in vivo immunotherapy

Innorna is one of the few clinical-stage mRNA companies with fully vertically integrated in-house manufacturing capabilities — from lipid synthesis and mRNA production through LNP formulation and cGMP drug product fill-finish. This integration eliminates dependence on external CROs and CDMOs, enabling rapid iteration cycles, deep process know-how, and exceptional capital efficiency.